Confidential - Do not share without permission
Back
Confidential - Do not share without permission
Back
Performance
-
-
Developer of an implantable brain-machine interface designed to treat patients with extreme disabilities. The company's device is an advanced optogenetic visual prosthesis for patients with serious blindness due to photoreceptor loss, that uses light sent through a patient's optic nerve to transmit information, enabling doctors to treat serious brain diseases.
Memo Highlights
Confidential
Do not share
Deck only available via Desktop
Highlights
Science Corp is a neural engineering company, founded by Max Hodak, the co-founder and president of Neuralink ($8B valuation). Their first product has enabled them to successfully restore vision to patients with advanced late-stage macular degeneration (blindness) through its development of brain computer interfaces (BCIs) and biohybrid neural solutions. With $160 million in total funding, it ranks as the 2nd most funded BCI venture behind Neuralink. Its flagship product, the Science Eye, aims to restore vision for the blind using optogenetics and microLED technology, while its broader mission includes advancing biohybrid neural interfaces for high-bandwidth brain interaction. The company has published early research demonstrating feasibility and operates a robust R&D pipeline, Science Corp presents a compelling opportunity in the growing neurotech market.
Biotechnology has made enormous strides in the past few decades, yet the translation of cutting-edge scientific discoveries into tangible products that solve real-world health challenges often lags behind the pace of discovery. Key problems include:
For patients, this can mean slower access to life-changing (or life-saving) therapies and medical technologies. From a broader perspective, the biotech ecosystem needs more integrated, fast-moving companies that can rapidly prototype, iterate, and bring breakthrough solutions to market. Worldwide, an estimated 4.9 million people live with degenerative retinal conditions such as macular degeneration, retinitis pigmentosa, and Stargardt’s disease — leading to severe vision loss or blindness.
Existing therapies offer only partial solutions:
The broader challenge lies in creating high-bandwidth, biohybrid interfaces capable of interfacing with complex neural circuits — vital not only for vision restoration, but also for addressing paralysis, cognitive impairments, and other debilitating neurological conditions.
On a broad scale, Science Corporation aims to serve as a vertically integrated biotech platform that can accelerate the transition from early-stage research to commercial deployment. By leveraging deep expertise in engineering, biology, and clinical development, they seek to:
This unified approach promises to deliver life-altering medical and neural technologies faster and more efficiently than conventional biotech pathways.
Currently, Science Corp is primarily dedicated to addressing the challenge of blindness. Specifically targeting the largest patient population currently afflicted by blindness… In degenerative retinal diseases, such as age-related macular degeneration or retinitis pigmentosa, the photoreceptors (rods and cones) fail, leading to blindness. By stimulating the bipolar cells directly, bypassing the lost rods and cones, visual input can be restored to the brain.
Science Corp offers an integrated “biohybrid neural” approach, combining advanced microfabrication, optogenetics, and neural engineering in a single pipeline:
By commercializing the near-term subretinal implant and advancing high-impact R&D, Science Corp aims to restore sight for millions while developing next-generation BCIs to treat a broader spectrum of neurological disorders.
Research and IP
Max Hodak (CEO & Founder): Co-founder and former President of Neuralink, recognized for pioneering BCI work. States overarching goal to “engineer experience directly,” bridging neuroscience and advanced bioengineering.
Key Team Members
Culture & Vertical Integration
The convergence of biology, data, and engineering sets the stage for transformativeproducts that can meaningfully disrupt traditional biotech and medtech paradigms.
Large and Growing Market: The global biotech industry is projected to exceed $2 trillion by 2030, driven by increased demand for novel therapeutics and the rise of personalized medicine. Neurotechnology alone is expected to grow significantly due to an aging population and surging research into neurological disorders.
High-Value Therapeutic Areas: Severe neurological conditions and sensory impairments represent multibillion-dollar markets with limited existing solutions. As evidenced by Science’s revenue projections, a successful therapy or device in these indications can command strong pricing and large market share.
Platform Potential: Successful demonstration in one therapeutic area (e.g., restoring vision) can be expanded to other indications (e.g., spinal cord injuries, Parkinson’s disease, severe hearing loss), multiplying the addressable market.
With PRIMA as its cornerstone, Science Corp is poised to capture a meaningful share of this $600 billion market, contingent on successful clinical validation and scalability of its subretinal stimulation technology.
“Max Hodak, the founder of Science Corp., has raised $160 million in total funding, putting it second only to Elon Musk’s Neuralink, six years after co-founding the company and just a year after dumping Musk, Futurism reported.”
Science Corporation represents a significant opportunity in the rapidly evolving field of neurotechnology, specifically through their pioneering work in brain-computer interface (BCI) technology. The human nervous system remains one of medicine's most significant frontiers, with millions of patients worldwide suffering from devastating neurological conditions that have few or no effective treatments. Conditions resulting in vision loss, cognitive impairment, and mobility limitations represent enormous medical challenges with profound impacts on patient quality of life.
Current therapeutic approaches often fail to address the underlying neural mechanisms or provide only marginal improvements in function. Traditional pharmaceutical interventions frequently fall short for conditions involving complex neural pathway disruptions, while existing medical devices lack the sophisticated interface capabilities needed to effectively restore lost neurological functions
Additionally, the development pathway for neurotechnology has historically been fragmented, with researchers and clinical innovators facing significant barriers in translating promising concepts into viable therapeutic solutions due to manufacturing constraints, regulatory complexity, and technological limitations. This has created a substantial gap between the theoretical potential of neuroscience research and practical applications that can meaningfully improve patient outcomes in the real world.
The challenge is particularly acute in sensory restoration, where existing approaches providelimited functional recovery and often involve invasive procedures with significant risks. Similarly, mobility limitations caused by neurological damage or disease remain inadequately addressed by current technology, leaving patients dependent on basic assistive devices rather than solutions that directly interface with neural pathways. These conditions not only diminish quality of life but also impose enormous economic burdens on healthcare systems and caregivers, creating a pressing need for transformative approaches that can restore fundamental capabilities to affected individuals.
In conclusion, there are three primary driving factors:
Science Corp sits at the forefront of a multi-billion-dollar shift in neurotechnology, driven by:
Memo
Science Corp is a neural engineering company, founded by Max Hodak, the co-founder and president of Neuralink ($8B valuation). Their first product has enabled them to successfully restore vision to patients with advanced late-stage macular degeneration (blindness) through its development of brain computer interfaces (BCIs) and biohybrid neural solutions. With $160 million in total funding, it ranks as the 2nd most funded BCI venture behind Neuralink. Its flagship product, the Science Eye, aims to restore vision for the blind using optogenetics and microLED technology, while its broader mission includes advancing biohybrid neural interfaces for high-bandwidth brain interaction. The company has published early research demonstrating feasibility and operates a robust R&D pipeline, Science Corp presents a compelling opportunity in the growing neurotech market.
Biotechnology has made enormous strides in the past few decades, yet the translation of cutting-edge scientific discoveries into tangible products that solve real-world health challenges often lags behind the pace of discovery. Key problems include:
For patients, this can mean slower access to life-changing (or life-saving) therapies and medical technologies. From a broader perspective, the biotech ecosystem needs more integrated, fast-moving companies that can rapidly prototype, iterate, and bring breakthrough solutions to market. Worldwide, an estimated 4.9 million people live with degenerative retinal conditions such as macular degeneration, retinitis pigmentosa, and Stargardt’s disease — leading to severe vision loss or blindness.
Existing therapies offer only partial solutions:
The broader challenge lies in creating high-bandwidth, biohybrid interfaces capable of interfacing with complex neural circuits — vital not only for vision restoration, but also for addressing paralysis, cognitive impairments, and other debilitating neurological conditions.
On a broad scale, Science Corporation aims to serve as a vertically integrated biotech platform that can accelerate the transition from early-stage research to commercial deployment. By leveraging deep expertise in engineering, biology, and clinical development, they seek to:
This unified approach promises to deliver life-altering medical and neural technologies faster and more efficiently than conventional biotech pathways.
Currently, Science Corp is primarily dedicated to addressing the challenge of blindness. Specifically targeting the largest patient population currently afflicted by blindness… In degenerative retinal diseases, such as age-related macular degeneration or retinitis pigmentosa, the photoreceptors (rods and cones) fail, leading to blindness. By stimulating the bipolar cells directly, bypassing the lost rods and cones, visual input can be restored to the brain.
Science Corp offers an integrated “biohybrid neural” approach, combining advanced microfabrication, optogenetics, and neural engineering in a single pipeline:
By commercializing the near-term subretinal implant and advancing high-impact R&D, Science Corp aims to restore sight for millions while developing next-generation BCIs to treat a broader spectrum of neurological disorders.
Research and IP
Max Hodak (CEO & Founder): Co-founder and former President of Neuralink, recognized for pioneering BCI work. States overarching goal to “engineer experience directly,” bridging neuroscience and advanced bioengineering.
Key Team Members
Culture & Vertical Integration
The convergence of biology, data, and engineering sets the stage for transformativeproducts that can meaningfully disrupt traditional biotech and medtech paradigms.
Large and Growing Market: The global biotech industry is projected to exceed $2 trillion by 2030, driven by increased demand for novel therapeutics and the rise of personalized medicine. Neurotechnology alone is expected to grow significantly due to an aging population and surging research into neurological disorders.
High-Value Therapeutic Areas: Severe neurological conditions and sensory impairments represent multibillion-dollar markets with limited existing solutions. As evidenced by Science’s revenue projections, a successful therapy or device in these indications can command strong pricing and large market share.
Platform Potential: Successful demonstration in one therapeutic area (e.g., restoring vision) can be expanded to other indications (e.g., spinal cord injuries, Parkinson’s disease, severe hearing loss), multiplying the addressable market.
With PRIMA as its cornerstone, Science Corp is poised to capture a meaningful share of this $600 billion market, contingent on successful clinical validation and scalability of its subretinal stimulation technology.
“Max Hodak, the founder of Science Corp., has raised $160 million in total funding, putting it second only to Elon Musk’s Neuralink, six years after co-founding the company and just a year after dumping Musk, Futurism reported.”
Science Corporation represents a significant opportunity in the rapidly evolving field of neurotechnology, specifically through their pioneering work in brain-computer interface (BCI) technology. The human nervous system remains one of medicine's most significant frontiers, with millions of patients worldwide suffering from devastating neurological conditions that have few or no effective treatments. Conditions resulting in vision loss, cognitive impairment, and mobility limitations represent enormous medical challenges with profound impacts on patient quality of life.
Current therapeutic approaches often fail to address the underlying neural mechanisms or provide only marginal improvements in function. Traditional pharmaceutical interventions frequently fall short for conditions involving complex neural pathway disruptions, while existing medical devices lack the sophisticated interface capabilities needed to effectively restore lost neurological functions
Additionally, the development pathway for neurotechnology has historically been fragmented, with researchers and clinical innovators facing significant barriers in translating promising concepts into viable therapeutic solutions due to manufacturing constraints, regulatory complexity, and technological limitations. This has created a substantial gap between the theoretical potential of neuroscience research and practical applications that can meaningfully improve patient outcomes in the real world.
The challenge is particularly acute in sensory restoration, where existing approaches providelimited functional recovery and often involve invasive procedures with significant risks. Similarly, mobility limitations caused by neurological damage or disease remain inadequately addressed by current technology, leaving patients dependent on basic assistive devices rather than solutions that directly interface with neural pathways. These conditions not only diminish quality of life but also impose enormous economic burdens on healthcare systems and caregivers, creating a pressing need for transformative approaches that can restore fundamental capabilities to affected individuals.
In conclusion, there are three primary driving factors:
Science Corp sits at the forefront of a multi-billion-dollar shift in neurotechnology, driven by: